Polymeric nanoparticles modified with fatty acids encapsulating betamethasone for anti-inflammatory treatment

Silva, Catarina Oliveira; Rijo, Patrícia; Molpeceres, Jesús; Figueiredo, Isabel V.; Ascensão, Lia; Fernandes, Ana Sofia; Roberto, Amílcar; Reis, Catarina Pinto

doi:10.1016/j.ijpharm.2015.07.044

Cited by 69 publications

(36 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These empty nanoparticles also demonstrated a concentration-dependent toxic effect on the human keratinocyte HaCaT cell line [42,49,50]. In addition, our empty PLGA nanoparticles was already tested using the human keratinocyte HaCaT cell line [48] and corroborates with the present study. …”

Section: Resultssupporting

confidence: 89%

“…Cytotoxicity profiles for nanosystems are not yet well understood. Other examples of our group such as polycaprolactone nanoparticles with betamethasone-21-acetate confirmed the occlusive effect of nanocarriers [48]. In this case, betamethasone-21-acetate showed an IC 50 of 168.8 µg/mL and betamethasone-21-acetate-loaded nanoparticles showed an IC 50 of 14.5 µg/mL.…”

Section: Resultssupporting

confidence: 68%

See 1 more Smart Citation

Design of Finasteride-Loaded Nanoparticles for Potential Treatment of Alopecia

Roque

Dias²,

Cruz³

et al. 2017

Skin Pharmacol Physiol

Self Cite

View full text Add to dashboard Cite

Background/Aims: Androgenetic alopecia is an extremely common dermatological disorder affecting both men and women. Oral finasteride (FNS), a synthetic 4-aza-3-oxosteroid compound with poor aqueous solubility, blocks the peripheral conversion of testosterone to dihydrotestosterone (DHT) in a significant reduction in DHT concentration, achieving satisfactory results in alopecia treatment. However, its oral intake generally causes severe side effects. Considering that there is currently no scientifically proven treatment, new drug delivery systems able to improve alopecia therapy are urgently required. Methods: In this study, polymeric nanoparticles have been proposed as a new carrier for topical delivery of FNS in hair follicles. Results and Conclusions: Polymeric nanoparticles, prepared by using a modified method of the emulsification/solvent diffusion, showed a mean particle size around 300 nm, which may be sufficient for reaching the dermis and hair follicles and negative zeta potential values. Scanning electron microscope measurements showed that all the polymeric nanoparticles exhibited a spherical shape and a smooth surface regardless of their composition. A high encapsulation efficiency was achieved for FNS (79.49 ± 0.47%). In vitro release assays in physiological conditions demonstrated that nanoparticles yielded a prolonged release of FNS for 3 h. Skin assays through an in vitro permeation study demonstrated that nanoparticles had low levels of penetration of FNS, improving its time residence onto the skin. All excipients used in nanoparticle composition and in 3 different vehicles were safe. These results suggest that the proposed novel formulation presents several good characteristics indicating its suitability for dermal delivery of FNS for alopecia treatment.

show abstract

Section: Resultssupporting

confidence: 89%

Section: Resultssupporting

confidence: 68%

Design of Finasteride-Loaded Nanoparticles for Potential Treatment of Alopecia

Roque

Dias²,

Cruz³

et al. 2017

Skin Pharmacol Physiol

Self Cite

View full text Add to dashboard Cite

show abstract

“…In recent years, polymeric nanoparticles composed of biocompatible and biodegradable polymers have received increasing attention as a modern approach for dermal drug delivery. Thanks to their synthetic nature, one is able to precisely tailor polymeric particles with efficient, site specific and environmentally controlled drug release, which alongside the use of biocompatible polymers, can greatly improve the safety profiles of such therapies [4][5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Tailored dendritic core-multishell nanocarriers for efficient dermal drug delivery: A systematic top-down approach from synthesis to preclinical testing

Hönzke

Gerecke

Elpelt

et al. 2016

Journal of Controlled Release

View full text Add to dashboard Cite

“…22,[24][25][26][27][28][29][30] These nanocarriers facilitate drug delivery to structural features of the skin, such as hair follicles, or interact with skin lipids to mediate transportation and create a drug depot in the skin for sustained release. 31,32 Moreover, cationic nanoparticles have shown advantages of enhancing drug permeation over neutral or negatively charged nanoparticles as drug nanocarriers; significant progress has been made in cationic nanoparticles for drug delivery. 33,34 In the present study, chitosan nanoparticles (CS-NPs) were used as the carrier of FK506 for percutaneous delivery.…”

Section: Introductionmentioning

confidence: 99%

Tacrolimus nanoparticles based on chitosan combined with nicotinamide: enhancing percutaneous delivery and treatment efficacy for atopic dermatitis and reducing dose

Yu¹,

Wang²,

Wan³

et al. 2017

IJN

View full text Add to dashboard Cite

Background Topical application of tacrolimus (FK506) was effective in the treatment of atopic dermatitis (AD); however, adverse effects frequently occurred with the increase of FK506 dose during long–term treatment. Objective The objective of this project was to develop a hybrid skin targeting system encapsulating FK506 based on nicotinamide (NIC) and chitosan nanoparticles (CS–NPs), ie, FK506–NIC–CS–NPs, which took advantages of both of NIC and CS–NPs to obtain the synergetic effects of percutaneous delivery and treatment efficacy enhancement along with dose reduction. Methods The formulation of FK506–NIC–CS–NPs was optimized and characterized. In vitro and in vivo skin permeation studies were performed. AD–like skin lesions were constructed with BALB/c mice by 1–chloro–2, 4–dinitrobenzene (DNCB)–induced, and FK506–NIC–CS–NPs containing different dose of FK506 were topically administered to treat AD–like skin lesions in comparison with Protopic. Results NIC was found to significantly increase the FK506 EE to 92.2% by CS–NPs. In comparison with commercial FK506 ointment (Protopic), in vitro and in vivo skin permeation studies demonstrated that NIC–CS–NPs system significantly enhanced FK506 permeation through and into the skin, and deposited more FK506 into the skin. The treatment efficacy on clinical symptoms, histological analysis, and molecular biology of the AD–mice demonstrated that NIC–CS–NPs with ~1/3 dose of FK506 of Protopic was superior to that of Protopic, and NIC–CS–NPs vehicle exhibited the adjuvant therapy and moderate anti–AD effects. Conclusion The system of NIC–CS–NPs enhances the permeability of FK506, plays an adjuvant role in anti-AD, reduces the dose of FK506 in treating AD, and is therefore a promising nanoscale system of FK506 for the effective treatment of AD.

show abstract

Polymeric nanoparticles modified with fatty acids encapsulating betamethasone for anti-inflammatory treatment

Cited by 69 publications

References 47 publications

Design of Finasteride-Loaded Nanoparticles for Potential Treatment of Alopecia

Design of Finasteride-Loaded Nanoparticles for Potential Treatment of Alopecia

Tailored dendritic core-multishell nanocarriers for efficient dermal drug delivery: A systematic top-down approach from synthesis to preclinical testing

Tacrolimus nanoparticles based on chitosan combined with nicotinamide: enhancing percutaneous delivery and treatment efficacy for atopic dermatitis and reducing dose

Contact Info

Product

Resources

About